Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma.

Gollob JA, Veenstra KG, Parker RA, Mier JW, McDermott DF, Clancy D, Tutin L, Koon H, Atkins MB.

J Clin Oncol. 2003 Jul 1;21(13):2564-73.

PMID:
12829677
2.

IL-12 induces monocyte IL-18 binding protein expression via IFN-gamma.

Veenstra KG, Jonak ZL, Trulli S, Gollob JA.

J Immunol. 2002 Mar 1;168(5):2282-7.

3.

Agranulocytosis and hemolytic anemia in patients with renal cell cancer treated with interleukin-12.

Gollob JA, Veenstra KG, Mier JW, Atkins MB.

J Immunother. 2001 Jan-Feb;24(1):91-8.

PMID:
11211153
4.

Impairment of STAT activation by IL-12 in a patient with atypical mycobacterial and staphylococcal infections.

Gollob JA, Veenstra KG, Jyonouchi H, Kelly AM, Ferrieri P, Panka DJ, Altare F, Fieschi C, Casanova JL, Frank DA, Mier JW.

J Immunol. 2000 Oct 1;165(7):4120-6.

5.

Ras- and Raf-induced down-modulation of non-muscle tropomyosin are MEK-independent.

Janssen RA, Veenstra KG, Jonasch P, Jonasch E, Mier JW.

J Biol Chem. 1998 Nov 27;273(48):32182-6.

Supplemental Content

Loading ...
Support Center